blindness from glp 1 with NAION and GLP1s: Rare Cause of Linked to Medication GLP-1 NAION Vision Loss Lawsuit

doi: 10.1111/j.1365-313X.2004.02020.x

and Leon, J.D

corresponding with a 2-fold increase in insulin secretion by islets treated for 24h with palmitate (67)

documented efficacy in improving desire scores and reducing distress associated with low libido Low libido in postmenopausal women: off-label use investigated where hormonal changes have reduced sexual desire and standard hormone therapy has not fully addressed the desire component Low sexual desire and erectile dysfunction in men: off-label use investigated for men where low libido (desire component) coexists with erectile difficulty, either as monotherapy or alongside PDE5 inhibitors Sexual dysfunction with psychological or stress-related components: PT-141's central mechanism may be particularly relevant where desire is suppressed by psychological factors rather than purely vascular ones Patients who have not responded adequately to PDE5 inhibitors alone: PT-141 adds the central desire component that PDE5i do not address PT-141 is the only FDA-approved medication that treats low sexual desire through a central neural mechanism rather than a peripheral vascular one

Growth Hormone Secretagogues: Ipamorelin, CJC-1295, Tesamorelin, and Sermorelin GH secretagogues are synthetic peptides that stimulate the pituitary gland to increase endogenous growth hormone secretion

You dont tilt it at any angle because of how small these needles are